Abstract: The present invention relates to a method for preparing a solution of a refolded, recombinantly expressed or chemically synthesized eukaryotic membrane protein in monodisperse form, to methods for preparing a crystalline form of a recombinantly expressed or chemically synthesized membrane protein, to a crystalline form of a recombinantly expressed, or chemically synthesized eukaryotic membrane protein, and to a crystalline form of a complex of a recombinantly expressed or chemically synthesized eukaryotic membrane protein and of an accessory agent.

Abstract: In a method for production of membrane receptors folded into their native structure, first, receptors solubilized in a first detergent are provided. To induce folding of receptors into their native form, the first detergent is exchanged for a second detergent. Both for the first and for the second detergent, examples are shown.

Abstract: A method of ion channels folded into their active structure, or functional subunits thereof, is described. For this purpose, initially expressed subunits, which are solubilized and denatured in a first detergent, of an ion channel are provided, and subsequently the first detergent is replaced by a second detergent which induces folding of the subunits of an ion channel into their native structure. The subunits of the ion channel are then assembled into its active structure.

Abstract: In a method for production of membrane proteins or receptors folded into their native structure, first, proteins solubilized in a first detergent are provided. To induce folding of proteins into their native form, the first detergent is exchanged for a second detergent. Both for the first and for the second detergent, examples are shown.

Abstract: The present invention relates to a method for preparing a solution of a refolded, recombinantly expressed or chemically synthesized eukaryotic membrane protein in monodisperse form, to methods for preparing a crystalline form of a recombinantly expressed or chemically synthesized membrane protein, to a crystalline form of a recombinantly expressed, or chemically synthesized eukaryotic membrane protein, and to a crystalline form of a complex of a recombinantly expressed or chemically synthesized eukaryotic membrane protein and of an accessory agent.

Abstract: In a process for preparing dry, free-flowing choline chloride-containing powders by atomizing an aqueous choline chloride solution, a colloid-free aqueous choline chloride solution is atomized in a countercurrent-flowing air stream that contains, finely dispersed, a hydrophobic spraying auxiliary metered in in such amounts that the sprayed choline chloride droplets are coated with 2 to 15% by weight of spraying auxiliary, based on choline chloride calculated as 100%, and the coated particles are, if desired, collected in a fluidized bed and dried in the gas stream.

Abstract: A process for preparing dl-.alpha.-tocopherol or dl-.alpha.-tocopheryl acetate by acid-catalyzed reaction of 2,3,5-trimethylhydroquinone (TMH) with phytol or isophytol in a solvent at elevated temperature, with or without subsequent esterification of the resulting tocopherol with acetic anhydride, entails the reaction being carried out in the presence of a mixture of ortho-boric acid and certain aliphatic di- or tricarboxylic acids, preferably in the presence of a mixture of ortho-boric acid and oxalic acid.

Abstract: A process for preparing spray granules or microgranules, which contain no binder, are non-dusting and free-flowing, from finely divided pure riboflavin, comprises subjecting an aqueous or water-containing suspension of the pure finely divided riboflavin toa) a fluidized bed spray dryingb) a single-nozzle spray drying orc) a disk-type spray dryingin particular a fluidized bed spray drying, without adding binders to the suspension, and the spray granules or microgranules of riboflavin obtainable by this process.

Abstract: A process for preparing formic acid by thermal cleavage of quaternary ammonium formates of the general formula I ##STR1## where R.sup.1, R.sup.2 and R.sup.3 are C.sub.1 - to C.sub.14 -alkyl, C.sub.3 - to C.sub.8 -cycloalkyl, aryl or C.sub.7 - to C.sub.16 -aralkyl, or together are 1,4- or 1,5-alkylene which is unsubstituted or substituted one to four times by C.sub.1 -to C.sub.4 -alkyl, with the proviso that the sum of the carbon atoms of R.sup.1, R.sup.2 and R.sup.3 in the quaternary ammonium formates I is 7 to 40,comprises carrying out the cleavage in the presence of secondary formamides of the general formula II ##STR2## where R.sup.4 and R.sup.5 are C.sub.2 - to C.sub.10 -alkyl, C.sub.3 - to C.sub.8 -cycloalkyl, aryl or C.sub.7 - to C.sub.16 -aralkyl, or together are 1,4- or 1,5-alkylene which is unsubstituted or substituted one to four times by C.sub.1 - to C.sub.4 -alkyl,which formamides boil 30.degree. to 150.degree. C. lower than the tertiary amine of the general formula III ##STR3## where R.sup.1, R.

Abstract: A method of purifying ferment-produced riboflavin, wherein the impure riboflavin is suspended in water or dilute aqueous acid, and the suspension is heated at a temperature of from 75.degree. to 130.degree. C. for from 0.3 to 3 hours with stirring, during which time crystal transformation takes place, after which the mixture is cooled and the purified product is isolated in known manner.

Abstract: Anhydrous or substantially anhydrous formic acid is prepared by hydrolyzing methyl formate in the presence of a formamide and then obtaining the formic acid from the hydrolysis mixture by distillation, by a method in which the hydrolysis is carried out in the presence of 0.5-3 moles, per mole of methyl formate, of a water-soluble formamide of the general formula I ##STR1## where R.sup.1 and R.sup.2 are each alkyl or together form an alkylene group, giving a 5-membered to 7-membered ring, with the proviso that the sum of the carbon atoms in R.sup.1 and R.sup.2 is 5 or 6 and, in the case of an alkylene group, a carbon atom which is not directly bonded to the N atom can be replaced by an oxygen atom.

Abstract: A process for the isolation of a carboxylic acid of the general formula (I)R.sup.1 --COOH (I),in which R.sup.1 denotes hydrogen, methyl, ethyl, or vinyl, from a dilute aqueous solution thereof by extraction with a secondary amide of the general formula (II) ##STR1## in which R.sup.1 has the meanings stated, and R.sup.2 and R.sup.3 are independently of each other C.sub.1 -C.sub.8 -alkyl, C.sub.3 -C.sub.8 -cycloalkyl, C.sub.4 -C.sub.20 -cycloalkylalkyl, aryl, C.sub.7 -C.sub.20 -aralkyl, or R.sup.2 and R.sup.3 together form a 1,4- or 1,5-alkylene group which may be mono- to penta-substituted by C.sub.1 -C.sub.4 -alkyl, wherein the losses of secondary amide (II) are compensated by the addition of the corresponding amine of the general formula (III) ##STR2## in which R.sup.2 and R.sup.3 have the meanings stated above.

Abstract: Powdered and/or granulated menadione sodium bisulfite formulations additionally contain a physiologically tolerated organic or inorganic acid.The novel formulations possess good water solubility and stability.

Abstract: An improved process for preparing riboflavin 5'-phosphate (FMN) or its monosodium salt by reacting riboflavin with excess phosphorus oxychloride in a solvent, hydrolyzing of the resulting reaction mixture and, if desired, partially neutralizing with aqueous sodium hydroxide solution, comprises reacting the riboflavin with from 1.2 to 3 moles of phosphorus oxychloride per mole of riboflavin in a suitable lactone, especially .gamma.-butyrolactone, as solvent. The process is particularly advantageous when the reaction mixture is hydrolyzed at from 80.degree. to 90.degree. C. continuously or batchwise.

Abstract: Riboflavin-4',5'-cyclophosphoric acid chloride of the formula I ##STR1## its preparation by reacting an alkali metal salt of riboflavin, in an aprotic solvent, with phosphorus oxychloride, its use for the preparation of riboflavin-5'-phosphate and of the sodium salt of riboflavin-5'-phosphate, and a process for the preparation of riboflavin-5'-phosphate or its sodium salt via the novel phosphoric acid ester chloride.

Abstract: Riboflavin produced by a microbial method is prepared in the form of free-flowing, non-dusting, spray-dried granules or microgranules as a feed additive by removing water from the mixture discharged from microbial fermentation for the preparation of riboflavin, wherein the mixture is subjected to(a) a fluidized-bed spray-drying process(b) a one-material spray-drying process or(c) a disk spray-drying process without significant amounts of binders being added to the discharged fermentation mixture.

Abstract: A method of determining radiation doses by evaluation of nuclear tracks in an irradiated foil of track recording material through the use of an electrochemical etching cell which is subdivided into two chambers by the foil with the irradiated side of the foil contacted by a mixture of an etchant and a solvent and the opposite side of the foil contacted by an electrolyte and with a first electrode immersed into the mixture and a second immersed into the electrolyte, the method including the steps of: (a) applying an alternating voltage across the two electrodes establishing an electric field through the foil; (b) etching the nuclear tracks by selective exposure to the mixture for a given period of time in the presence of the electric field; (c) continuously recording the electrical capacitance between the electrodes during the performance of step (b); and (d) comparing the electrical capacitance reached after a given etching time with a calibrated value for obtaining a measure for the radiation dose.

Abstract: An animal feed or drinking water contains a biocidally or biostatically active amount of not less than one formic acid ester of 1,2-propanediol.

Abstract: A novel bisulfite adduct of menadione, the menadione choline bisulfite adduct, a process for its preparation, and its use as an antihemorrhagic agent.

Abstract: In a passive dosimeter including a diffusion chamber having an interior space, and an alpha particle detector located within the chamber for producing an indication of the concentration of radon and thoron gas and decay products and the relative percentages of radon and thoron individually, the diffusion chamber is constructed so that the interior space is open to the outside, the size of the detector and of the interior space are selected for causing the differences in path length of alpha particles in the interior space to permit the emission energy to be determined independently of the location of decay events, and the surface of the chamber bordering the interior space is electrically conductive.